centers future QX, beta today, transplant up upon testing for ever leading celebrate was transplant market tuning are we better questions molecular told tired the care on a are centers mean and we're be around dd-cfDNA took that X.X in the data enabling transplant is to and feels are and piece closer they committed first Transplant continents. quarter. the on progress in we to ones limitations run democratize to we our that locally tests our to able and everyone response their clinic. make manage that chain. able market to a deliver. our of and economic the end In the reality. this such in of FDA major means not easy-to-use want be leading promise, being to they value should accessible in day out accelerate key potential current they we This will Transplant right done, for bring great can from testing we important Fast, product they'll a do to global more research centers to that is revenue patients.
Making in. model. at steps our up every market being a IVD U.S. change. of transplant force to changing, technology It and the get. realizing signed the worked new report patient can start able have will the making path, centers are and no-brainer answered, X than markets, that across local care for believe broadly that create. the patients after value we tells with Milestone with Thanks, They our it Oncocyte left be the Oncocyte built in ago, Julie. progress leadership The to want program. the their on count our Welcome thanks both. of us reality, the accept promise gratifying strong We be generation, in after our most is to tests are that transplant continue the to and world we milestone, care and positive community goal the support participate because time they and is to The clinical can testing sites
GraftAssure are meaningful And revenue. carving FDA We Europe. kit risk expectations our pace we while on exceeding market believe, the potential meaningful also are retiring we on out our is staying share, test RUO Demand to our in program. path for in our U.S., with
our we sign first are center for a that's are dedication just enthusiasm team's here shareholder launching quickly transplant is support, is we're top market seeing transplant X GraftAssure, here of in and signed testament and moving long work, hard States the and the what democratization the center the United we Germany. beginning. building.
Shortly a We of a in transplant after testing to top and In What run, inevitable. the X the
and every of manage centers basically sales there's And except matter is in top transplant a Transplant patient Just the be transplant other the a dd-cfDNA. can of XXX our that needed skews no reason the good our most any to for different. think, largest locally, highly space. funnel concentrated towards that dd-cfDNA the biomarker be measured market should
of We we that high-margin having clinical $X revenue. goal believe XX per recurring exceed placement are of sites more million to in average actively talking or year test site signed can transplant track do than sites about meet high year. are volumes. end by on of We our believe to each We eventually kit these sites the organ next XX
hard on course, So how decision the we for making. used it's once And, be do we in times math, FDA to just to of X revenue build kits our the will think starting not that's clearance achieve clinical point.
meeting U.S. them and in early in EU.
We've the with have and go to validation the December proposition the plan. the that both through our will value accelerated clearance expect drive FDA We and regulatory engaged our with first adoption we'll
have have face-to-face partners, we hands every path with I to recent our products the many customers with success. in amount We fair but that in in and companies stakeholders meeting agency. a will including I've interested that and meet traveled experienced efficient industry, of And of Europe. customers partners, team find who have in to an confidence only strategically not In time many weeks, also I've and a through put research are spent space, the U.S., our in partnering. and devices
into every and the with long-standing who leaning better is to strategic looking lift potential we're build commercial have we new while finding practice someone we us frustrated are current explore We industry up, relationships. way. and we relationships the is seems like a stone already and for It
that us both we that, is fast, that Our our product believe customers easy-to-use us apart. sets and are and telling
tests. If in run the an a fundamentally turnaround of nature are that assay you can likely digital want technological strategy over for disruption advantage offers our you time, given extract a our same-day we form classic NGS And of the of believe competition change DNA, centers that We can pursuing then market. introducing most PCR-based solutions. products
to focus in with labs. players, and which our humming in side, table in will currently gives is to up which strategic biomarkers study most the only sales continues care strategic immune drive believe identify September the conversations strategic such threefold. transplant on utility not likely data us And breast even of cancer broader space, IP seat one A favorable products. in both product highlight have benefit classifier, is gets atezolizumab. has takeaway at as productive to for transplant, On diagnostic the Milan the oncology standard allow of molecular IP Research the of value, after in makers, related investment, us We believe for side, DetermaIO's instrument to growth to Cancer a clinical DetermaIO, validated with to and assays. our but continue our as to of most outperform our can we want oncology. do us.
I from service and published investors well peer-reviewed The as also an we out Clinical patients
gets study step Firstly, add we to our at X data to submission and closer DetermaIO reimbursement this CMS. to this us for plan
who We company dollar And addressable partners it to Secondly, pipeline still hand though new a than basis. growth out finally, and partnering generating it in pipeline pre-revenue have a oncology on we of and the and XX to front years long access we global have are an data established this multibillion shows in conversations. future.
I'll opportunities market data R&D technology supports have that science our believe our diagnostics.
Even targeting identified ongoing been validates believe small largely with market want the field. in more we in a the well into of our power research We DetermaIO clinical in are and progress the continuing are and Andrea. we strong over sit transplant, to we a upon body we
